Key features
Investment approach geared towards long-term structural growth opportunities – focus on companies versus countries
Emphasis on companies with franchise sustainability and attractive valuations
Dedicated emerging markets team has managed the Fund since 2006
Total net assets
as of
10/31/2023
All share classes
$537.2 million
Overview
Benchmark
Portfolio
International equities & depositary receipts
100.0%
Top 10 holdings
as of 10/31/2023
Holdings are as of the date indicated and subject to change.
List may exclude cash and cash equivalents. Please see the Series' complete list of holdings for more information.
Holdings based by issuer.
TAIWAN SEMICONDUCTOR MANUFACTURING CO LT
11.42
SAMSUNG ELECTRONICS CO LTD
9.93
RELIANCE INDUSTRIES LTD
9.01
TENCENT HOLDINGS LTD
5.19
KWEICHOW MOUTAI CO LTD
4.80
ALIBABA GROUP HOLDING LTD
4.05
WULIANGYE YIBIN CO LTD
3.32
Total % Portfolio in Top 10 holdings - 62.32%
Credit quality as of //
Management
Liu-Er Chen, CFA
-
Managing Director, Chief Investment Officer – Emerging Markets and Healthcare Equity
-
Start date on the Fund:
September 2006
-
Years of industry experience:
28
-
Read bio
Liu-Er Chen
Managing Director, Chief Investment Officer – Emerging Markets and Healthcare Equity
- Joined Delaware Investments in 2006, acquired by Macquarie in 2010
- Based in Boston
Liu-Er is the Chief Investment Officer for the Emerging Markets Equity Team at Macquarie Asset Management (MAM), responsible for managing for the firm’s emerging markets equity portfolios and Delaware Healthcare Fund, a role he first assumed with Delaware Investments in September 2007.
Before joining Delaware Investments, Liu-Er worked at Evergreen Investment Management Company for nearly 11 years, where he was the sole manager of the Evergreen Health Care and Emerging Markets funds. Prior to his career in asset management, Liu-Er worked in sales, marketing, and business development for major American and European pharmaceutical and medical device companies.
Liu-Er earned a Master of Business Administration from Columbia Business School and holds the Chartered Financial Analyst® designation.
Fees
The following table describes the fees and expenses that you may pay if you buy, hold, and sell shares of the Series. The fee table does not reflect any fees or sales charges imposed by variable insurance contracts. If it did, the expenses would be higher.
Annual portfolio operating expenses |
Management fees |
1.24% |
Distribution and service (12b-1) fees |
none |
Other expenses |
0.17% |
Total annual portfolio operating expenses |
1.41% |
Fee waivers and expense reimbursements1 |
(0.23%) |
Total annual portfolio operating expenses after fee waivers and expense reimbursements |
1.18% |
Please see the prospectus and SAI for additional information.
1Net expense ratio reflects a contractual waiver of certain fees/and/or expense reimbursements from May 1, 2023 through April 30, 2024. Please see the fee table in the Portfolios' prospectus for more information.